|
Acquisitions (Details) (USD $)
In Millions, unless otherwise specified |
3 Months Ended | 12 Months Ended | 0 Months Ended | ||||||
|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2013
|
Sep. 30, 2013
|
Jun. 30, 2013
|
Mar. 31, 2013
|
Dec. 31, 2013
|
Dec. 31, 2012
|
Dec. 31, 2011
|
Jul. 07, 2011
Janssen Pharmaceutica NV (J&J) [Member]
|
Feb. 17, 2012
ChemGen [Member]
|
|
| Business Combination, Consideration Transferred | $ 307.8 | $ 206.9 | |||||||
| Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | 234.4 | 151.5 | |||||||
| Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets | 29.6 | ||||||||
| Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net | 43.8 | 55.4 | |||||||
| Business Acquisition, Products or Other Assets Acquired | 50 | ||||||||
| Acquired in-process research and development | $ 57.1 | $ 0 | $ 0 | $ 0 | $ 57.1 | $ 0 | $ 388.0 | ||